BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
"Our preclinical data highlight the potential of azelaprag as a novel oral therapy for obesity," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. “Our two presentations provide evidence ...
Yahoo Finance5d
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases ...
Investing1d
Bioage Labs Inc (BIOA)
This page features the latest news about the Bioage Labs stock. BioAge Labs director Enright buys $7.2 million in stock BioAge Labs, Inc. (NASDAQ:BIOA) has seen significant insider activity as ...
pharmaphorum2d
BioAge's $100m IPO, and other biotech financings
Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...